Altimmune Inc

+0.74 (+5.74%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)669.51M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.03 Million
Adjusted EPS-$0.50
See more estimates
10-Day MA$13.96
50-Day MA$12.67
200-Day MA$11.37
See more pivots

Altimmune Inc Stock, NASDAQ:ALT

910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878
United States of America
Phone: +1.240.654.1450
Number of Employees: 47


Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.